Mitra Sukanya, Khandelwal Purva
Associate Professor, Department of Anaesthesia & IntensiveCare, Government Medical College & Hospital, Chandigarh.
Indian J Anaesth. 2009 Oct;53(5):592-607.
The administration of intravenous fluids is one of the most common and universal interventions in medicine. Colloids are an alternative to the frequently used crystalloids, with highly variable use depending on a myriad of clinical variables. A colloid is defined as a high molecular weight (MW) substance that largely remains in the intravascular compartment, thereby generating an oncotic pressure. Colloids are considered to have a greater intravascular persistence when compared to crystalloids. All colloids, however, are clearly not the same. Differences in the physicochemical properties, pharmacokinetics and safety profile exist amongst various colloids. This review explores the different types of colloids, with their properties and usefulness as well as adverse effects. While all the available colloids are reviewed briefly (e.g., albumin, gelatin, dextran) with respect to their pharmacology, indications, advantages and disadvantages, particular emphasis is laid on the hydroxyethyl starches (HES) because of their rising prominence. It is shown that HES differ widely in their physicochemical and pharmacokinetic properties, composition, usefulness, and especially in their adverse effect profiles. The third generation HES (tetrastarches), in particular, seem to offer a unique combination of safety and efficacy. Several issues related to this are discussed in detail. This review of the available clinical data demonstrates that HES should not be regarded as one homogenous group, and data for one product should not be automatically extrapolated to another. Thus, among the synthetic colloids, the tetrastarches appear to offer the best currently available compromise between efficacy, safety profile, and cost. They also appear to be the best suited for use in the intensive care setting. Finally, balanced (rather than saline-based) HES solutions appear promising as a plasma-adapted volume replacement strategy and may further refine the ongoing quest of finding the ideal fluid therapy.
静脉输液是医学中最常见和普遍的干预措施之一。胶体是常用晶体液的替代物,其使用因众多临床变量而差异很大。胶体被定义为一种高分子量(MW)物质,它在很大程度上保留在血管内间隙,从而产生胶体渗透压。与晶体液相比,胶体被认为在血管内具有更长的存留时间。然而,并非所有胶体都是一样的。不同胶体在物理化学性质、药代动力学和安全性方面存在差异。本综述探讨了不同类型的胶体,包括它们的性质、用途以及不良反应。在简要回顾所有可用胶体(如白蛋白、明胶、右旋糖酐)的药理学、适应证、优缺点的同时,由于羟乙基淀粉(HES)日益突出,特别强调了它们。结果表明,HES在物理化学和药代动力学性质、组成、用途,尤其是不良反应方面差异很大。特别是第三代HES(四淀粉)似乎提供了安全性和有效性的独特组合。详细讨论了与此相关的几个问题。对现有临床数据的综述表明,HES不应被视为一个同质的群体,一种产品的数据不应自动外推到另一种产品。因此,在合成胶体中,四淀粉似乎在疗效、安全性和成本之间提供了目前最好的折衷方案。它们似乎也最适合在重症监护环境中使用。最后,平衡(而非基于生理盐水)的HES溶液作为一种适应血浆的容量替代策略似乎很有前景,可能会进一步完善寻找理想液体治疗方法的探索。